← Back to Search

Signal Processing

Speech Sound Feature Enhancement for Hearing Loss

N/A
Recruiting
Research Sponsored by University of Rochester
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Mild or moderate symmetric sensorineural hearing loss.
Normal hearing
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing how well people can understand speech when different aspects of the sound are changed.

Who is the study for?
This trial is for individuals with mild or moderate symmetric sensorineural hearing loss, as well as those with normal hearing. It's not suitable for people with asymmetric hearing thresholds greater than 15 decibels difference between ears up to 4 kHz, or severe hearing loss exceeding 60 dB at any frequency up to 4 kHz.
What is being tested?
The study is testing signal processing techniques designed to make speech sounds clearer by manipulating the rapid changes in frequency and amplitude that characterize spoken language. The goal is to improve intelligibility of speech for listeners.
What are the potential side effects?
Since this trial involves non-invasive signal processing methods rather than medication or surgery, traditional side effects are not applicable. Participants may experience fatigue from listening tasks or discomfort from wearing headphones.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have some hearing loss in both ears.
Select...
I have normal hearing.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Discrimination thresholds for formant-freq difference limens
Secondary study objectives
% of correct synthetic syllables
% of correct synthetic vowels
% of correct words

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Active Control
Group I: Normal HearingActive Control1 Intervention
Signal processing to improve intelligibility
Group II: Mild hearing lossActive Control1 Intervention
Signal processing to improve intelligibility
Group III: Moderate hearing lossActive Control1 Intervention
Signal processing to improve intelligibility

Find a Location

Who is running the clinical trial?

University of RochesterLead Sponsor
867 Previous Clinical Trials
548,682 Total Patients Enrolled
National Institute on Deafness and Other Communication Disorders (NIDCD)NIH
352 Previous Clinical Trials
180,989 Total Patients Enrolled

Media Library

Signal processing to improve intelligibility (Signal Processing) Clinical Trial Eligibility Overview. Trial Name: NCT03666676 — N/A
Sensorineural Hearing Loss Research Study Groups: Normal Hearing, Mild hearing loss, Moderate hearing loss
Sensorineural Hearing Loss Clinical Trial 2023: Signal processing to improve intelligibility Highlights & Side Effects. Trial Name: NCT03666676 — N/A
Signal processing to improve intelligibility (Signal Processing) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03666676 — N/A
~0 spots leftby Nov 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top